Conference Coverage

VIDEO: Biologics: Proposed guideline addresses perioperative management


 

AT THE ACR ANNUAL MEETING

“In addition, there are abundant observational data demonstrating an increase in infection in patients on chronic steroids greater than 15 mg, and we thought that part of the optimization of the patient would be getting them on the lowest possible steroid dose,” she said, stressing that this refers only to adults receiving glucocorticoids for their rheumatic disease, and not to those with a history of JIA who may have received steroids during development, or to those receiving glucocorticoids for primary, adrenal, or hypothalamic disease.

According to Dr. Goodman, the time is right for the introduction of these recommendations, because the increased use of disease-modifying drugs and biologics means that most patients coming in for these surgeries will be taking these medications.

Further, despite the widespread use of the medications, the rate of total knee and hip arthroplasty surgeries among patients with rheumatic diseases is about the same as it was 20 or 30 years ago – and their risk for devastating complications, including infections, remains high, she said, noting that appropriate medication management provides an opportunity to mitigate risk.

Coprincipal investigator, Bryan Springer, MD, further emphasized the importance of the guideline, noting that the 5-year survival among rheumatic disease patients who develop certain perioperative complications is lower than for many common cancers, and that the literature offers little guidance on managing medications in the perioperative period.

“We now have a document that’s based on the available evidence, and also based on expert opinion, to help us manage these patients much more thoroughly in the perioperative period,” Dr. Springer, an orthopedic surgeon in Charlotte, N.C., said during a press briefing on the guideline.

Dr. Springer highlighted the value of the unique collaboration between the ACR and the AAHKS, calling the effort a win both for patients, and for “collaborative efforts, collaborative research, which we just really don’t do enough of,” he said. “I hope this is a huge step towards that direction.”

This guideline development process was funded by the ACR and AAHKS.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Pages

Recommended Reading

Tips on how to differentiate CLE from dermatomyositis
MDedge Family Medicine
No difference in serious infection rates between SLE treatments
MDedge Family Medicine
Simtuzumab did not help IPF patients
MDedge Family Medicine
Be alert for dermatomyositis without muscle disease
MDedge Family Medicine
Anticipate, treat GI issues in scleroderma
MDedge Family Medicine
Autoimmune-mediated gut dysmotility puts patients at risk for bacterial overgrowth
MDedge Family Medicine
In lupus, optimize non-immunosuppressives to dial back prednisone
MDedge Family Medicine
Severe joint pain in adults with arthritis continues to rise
MDedge Family Medicine
Tryptase gene variant linked to GI, joint, and skin symptoms
MDedge Family Medicine
Tocilizumab makes big impression in giant cell arteritis treatment
MDedge Family Medicine